New strategies to prevent restenosis

American Journal of Cardiovascular Drugs

Volumn 1, Issue 2, 2001, Pages 77-83

  Kester, Mark ^a   Waybill, Peter ^a   Kozak, Mark ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPLASTY; ANIMAL; BRACHYTHERAPY; HUMAN; HYPERPLASIA; INTIMA; PATHOLOGY; PHOTOCHEMOTHERAPY; RECURRENT DISEASE; RESTENOSIS; REVIEW; STENT; ULTRASOUND;

ANGIOPLASTY; ANIMALS; BRACHYTHERAPY; CORONARY RESTENOSIS; HUMANS; HYPERPLASIA; PHOTOCHEMOTHERAPY; RECURRENCE; STENTS; TUNICA INTIMA; ULTRASONICS;

EID: 0008455919     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101020-00001     Document Type: Review

References (91)

1. Casterella PJ, Teirstein PS. Prevention of coronary restenosis Cardiol Rev 1999; 7; 219-31
2. von Birgelen C, Kutryk MJ, Serruys PW. Three-dimensional intravascular ultrasound analysis of coronary stent deployment and in-stent neointimal volume: current clinical practice and the concepts of TRAPIST, ERASER, and ITALICS. J Invasive Cardiol 1998; 10: 17-26
3. Quinn SF, Schuman ES, Hall L, et al. Venous stenoses in patients who undergo hemodialysis: treatment with self-expandable endovascular stents. Radiology 1992; 183: 499-504
4. Sapirstein W, Zuckerman B, Dillard J. FDA approval of coronary-artery brachytherapy. N Engl J Med 2001; 344: 297-9
5. Sheppard R, Eisenberg MJ. Intracoronary radiotherapy for restenosis. N Engl J Med 2001; 344: 295-7
6. Pasterkamp G, de Kleijn DP, Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications,? Cardiovasc Res 2000; 45: 843-52
7. Schwartz SM, Majesky MW, Murry CE. The intima: development and monoclonal responses to injury. Atherosclerosis 1995; 118 Suppl. 1: S125-40
8. Rosanio S, Tocchi M, Patterson C, et al. Prevention of restenosis after percutaneous coronary interventions: the medical approach. Thromb Haemost 1999; 82 Suppl. 1: 164-70
9. Wilcox JN, Waksman R, King SB, et al. The role of the adventitia in the arterial response to angioplasty: the effect of intravascular radiation. Int J Radiat Oncol Biol Phys 1996; 36: 789-96
10. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998; 81: 14E-17E
11. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system [editorial]. Circulation 1996; 93: 848-52
12. Lablanche JM, McFadden EP, Meneveau N, et al. Effect of nadroparin, a lowmolecular- weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale. Circulation 1997; 96: 3396-402
13. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998; 98: 1802-20
14. Bauters C, Meurice T, Hamon M, et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835-46
15. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999; 20: 58-69
16. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 1996; 77: 1045-51
17. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000; 35: 1103-15
18. The symphony investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators: Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000; 355: 337-45
19. Lablanche JM, Grollier G, Lusson JR, et al. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem. Circulation 1997; 95: 83-9
20. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997; 337: 365-72
21. Galassi AR, Tamburino C, Nicosia A, et al. A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Catheter Cardiovasc Interv 1999; 46: 162-8
22. O?Keefe Jr JH, McCallister BD, Bateman TM, et al. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1992; 19: 1597-600
23. Lehmann KG, Popma JJ, Werner JA, et al. Vascular remodeling and the local delivery of cytochalasin B after coronary angioplasty in humans. J Am Coll Cardiol 2000; 35: 583-91
24. Bertrand OF, Sipehia R, Mongrain R, et al. Biocompatibility aspects of new stent technology. J Am Coll Cardiol 1998; 32: 562-71
25. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000; 35: 1969-76
26. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-45
27. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-70
28. Jeong M, Ahn YK, Kang KT, et al. Reopro-coated stents inhibits porcine coronary stent thrombosis and restenosis [abstract]. Circulation 2000; 102 Suppl.: II-666
29. Chen SJ, Chen YF, Miller DM, et al. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. Circulation 1994; 90: 2468-73
30. Kullo IJ, Simari RD, Schwartz RS. Vascular gene transfer: from bench to bedside. Arterioscler Thromb Vasc Biol 1999; 19: 196-207
31. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995; 95: 1869-76
32. Rogers C, Groothuis A, Toegel G, et al. Paclitaxel release from inert polymer material-coated stents curtails coronary in-stent restenosis in pigs [abstract]. Circulation 2000; 102 Suppl.: II-566
33. Suzuki T, Bailey LR, Kopia GA, et al. Synergistic efficacy of anti-proliferative and anti-inflammatory therapies delivered by a stent [abstract]. Circulation 2000; 102 Suppl.: II-566
34. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 192-5
35. Winslow R. New heart stents deliver drugs to blockage site. Wall Street J 2001 Jan 12; B1
36. Moses J, Buller CEH, Nukta ED, et al. The first clinical trial comparing a coated-versus a non-coated coronary stent [abstract]. Circulation 2000; 102 Suppl.: II-664
37. Charles R, Sandirasegarane L, Yun J, et al. Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries. Circ Res 2000; 87: 282-8
38. Richardson BC, Lalwani ND, Johnson KJ, et al. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol 1994; 24: 2640-5
39. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res 2000; 87: 184-8
40. Dyet JF, Watts WG, Ettles DF, et al. Mechanical properties of metallic stents: how do these properties influence the choice of stent for specific lesions? Cardiovasc Intervent Radiol 2000; 23: 47-54
41. Garasic JM, Edelman ER, Squire JC, et al. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation 2000; 101: 812-8
42. Fisk MC. Patent victories reflect 2000 trend. National Law J 2001 Feb 19; 1
43. Seliger C, McCall R, Wolf WP, et al. Influence of a rough ceramic-like stent surface made of iriduim oxide on neointimal structure and thickening in an animal study [abstract]. Circulation 2000; 102 Suppl.: II-733
44. Windecker S, Mayer I, De Pasquale G, et al. Stent coating with titanium-nitric oxide for reduction of neointimal hyperplasia [abstract]. Circulation 2000; 102 Suppl.: II-567
45. King III SB, Meier B. Interventional treatment of coronary heart disease and peripheral vascular disease. Circulation 2000; 102 (special anniversary issue); IV81-6
46. Serfaty J, Yang X, Quick H, et al. MRI-guided coronary artery intervention [abstract]. Circulation 2000; 102 Suppl.: II-510
47. Komori H, Tamai H, Shiga M, et al. One year intravascular ultrasound followup of a new biodegradable self-expanding coronary stent in humans [abstract]. Circulation 2000; 102 Suppl.: II-641
48. Brieger D, Topol E. Local drug delivery systems and prevention of restenosis. Cardiovasc Res 1997; 35: 405-13
49. Lovich MA, Edelman ER. Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery. Circ Res 1995; 77: 1143-50
50. Rogers C, Karnovsky MJ, Edelman ER. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation 1993; 88: 1215-21
51. McLennan G, Johnson MS, Stookey KR, et al. Kinetics of release of heparin from alginate hydrogel [in process citation]. J Vasc Interv Radiol 2000; 11: 1087-94
52. Wong A, Amabile PG, Dake MD, et al. Perivascular controlled release of elastase limits neointimal formation in the angioplastied artery by directing migration of proliferating muscle cells away from the lumen [abstract]. Circulation 2000; 102 Suppl.: II-246
53. Bohl K, West JL. Nitric oxide-releasing hydrogels for the prevention of thrombosis and restenosis [abstract]. Circulation 2000; 102 Suppl.: II-734
54. Chang MW, Barr E, Seltzer J. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-22
55. Chang MW, Barr E, Lu MM, et al. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995; 96: 2260-8
56. Kibbe MR, Billiar TR, Tzeng E. Gene therapy for restenosis. Circ Res 2000; 86: 829-33
57. Ueno H, Yamamoto H, Ito S, et al. Adenovirus-mediated transfer of a dominant- negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol 1997; 17: 898-904
58. Engelse M, Lardenouye JHP, Lamfers MLM, et al. Adenovirus mediated overexpression of activin inhibits neointima formation in cultured human saphenous veins in vitro and in cuff-induced murine vadscular hyperplasia in vivo [abstract]. Circulation; 102 Suppl.: II-146
59. Todaka T, Yokoyama C, Yanamoto H, et al. Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. Stroke 1999; 30: 419-26
60. Zoldhelyi P, McNatt J, Xu XM. Prevention of arterial thrombosis by adenovirus- mediated transfer of cyclooxygenase gene. Circulation 1996; 93: 10-7
61. Rade JJ, Schulick AH, Virmani R, et al. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996; 2: 293-8
62. Shears II LL, Kibbe MR, Murdock AD, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998; 187: 295-306
63. Varenne O, Sinnaeve P, Gillijns H, et al. Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. Hum Gene Ther 2000; 11: 1329-39
64. Varenne O, Pislaru S, Gillijns H, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998; 98: 919-26
65. Song C, Klugherz B, Deflelice S, et al. Antibody tethered adenovirus for stentbased vector delivery in pig coronaries [abstract]. Circulation 2000; 102 Suppl.: II-566
66. Darius H, Buerke M, Boissel JP, et al. Local drug delivery and gene therapy [in German]. Herz 1997; 22: 347-54
67. Frimerman A, Welch PJ, Jin X, et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 1999; 99: 697-703
68. Asahara T, Chen D, Tsurumi Y, et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 1996; 94: 3291-302
69. Van Belle E, Tio FO, Chen D, et al. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol 1997; 29: 1371-9
70. Parikh SA, Edelman EA. Endothelial cell delivery for cardiovascular therapy. Adv Drug Deliv Rev 2000; 42: 139-61
71. Griese D, Ehsan AE, Mann MJ, et al. Local vascular transplantation of genetically modified blood-borne endothelial cells for cardiovascular tissue engineering and drug delivery [abstract]. Circulation 2000; 102 Suppl.: II-164
72. Teirstein PS, Massullo V, Jani S, et al. Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000; 101: 360-5
73. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000; 102: 951-8
74. Verin V, Popowski Y, de Bruyne B, et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. N Engl J Med 2001; 344: 243-9
75. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344: 250-6
76. Shroff S, Farb A, John MC, et al. Persistant neointimal inhibition with adverse edge effects 12 months after deployment of high dose 32P-beta emitting stents [abstract]. Circulation 2000; 102 Suppl.: II-421
77. John M, Schroff S, Farb A, et al. Long term 32P-beta emitting stents induce persistant dose-dependent arterial inflammation [abstract]. Circulation 2000; 102 Suppl.: II-421
78. Costa MA, Sabat M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999; 100: 789-92
79. Strauss B, Kutryk MJB, Sweet WL, et al. A new gamma emitting palladium- 103 stent prevents coronary artery in-stent restenosis in a swine model [abstract]. Circulation 2000; 102 Suppl.: II-422
80. Park S, Hong MK, Lee CW, et al. Rotational atherectomy and radiation therapy with 188re-MAG3-filled balloon for diffuse in-stent restenosis (R4 Trial) [abstract]. Circulation 2000; 102 Suppl.: II-422
81. Kossodo S, LaMuraglia GM. Clinical potential of photodynamic therapy in cardiovascular disorders. Am J Cardiovasc Drugs 2001; 1 (1): 15-21
82. LaMuraglia GM, ChandraSekar NR, Flotte TJ, et al. Photodynamic therapy inhibition of experimental intimal hyperplasia: acute and chronic effects. J Vasc Surg 1994; 19: 321-9; 329-31 [discussion]
83. Waters C, Wilson A, Bogetti T, et al. Photodynamic therpapy with the new photosensitizer drug, MV6401, results in targeted cell death of neointimal lesions in rat arteries [abstract]. Circulation 2000; 102 Suppl.: II-246
84. Belcaro G, Nicolides AN, Marlinghaus EH. Arterial thrombolysis with extracorporeal shock waves: a new non-invasive approach to acute arterial thrombosis [abstract]. Circulation 2000; 102 Suppl.: II-129
85. Post M, Moore P, Menahem N, et al. Intravascular sonotherapy prevents intimal hyperplasia in a coronary stent pig model without long term adverse effects [abstract]. Circulation 2000; 102 Suppl.: II-733
86. Amabile P, Waugh JW, Lewis TN, et al. In vivo plasmid-mediated gene delivery achieves viral efficiencies via intravascular ultrasound [abstract]. Circulation 2000; 102 Suppl.: II-147
87. Teupe C, Richter SL, Fisslthaler B, et al. Efficient local gene delivery by ultrasound- induced destruction of DNA-loaded albumin microbubbles [abstract]. Circulation 2000; 102 Suppl.: II-146
88. Yamasaki K, Tachibana T, Taniyama Y. Transfection of E2F decoy using novel non-viral safe and efficient ultrasound delivery method with microbubble agent (Optison) inhibits neointimal hyperplasia after balloon injury in rat carotid artery [abstract]. Circulation 2000; 102 Suppl.: II-247
89. Doukas J, Craig D, et al. Therapeutic angiogenesis induced by FGF2 gene delivery combined with laser transmyocardial revascularization [abstract]. Circulation 2000; 102 Suppl.: II-248-9
90. Sata M, Maejima Y, Nakajima H, et al. Genetic background influences ishemiainduced angiogenesis [abstract]. Circulation 2000; 102 Suppl.: II-248
91. Blindt R, Bosserhoff AK, Zeiffer U, et al. Comparison of cDNA expression in an in vitro restenosis model using a microarray system [abstract]. Circulation 2000; 102 Suppl.: II-246